<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501227</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 859.8</org_study_id>
    <nct_id>NCT01501227</nct_id>
  </id_info>
  <brief_title>Ventilator Associated Pneumonia in Taper Guard Versus Normal Tube in ICU Patients</brief_title>
  <official_title>Comparison of the Incidence of Ventilator Associated Pneumonia in Patients Intubated With the Taper Guard Endotracheal Tube Versus a Normal Endotracheal Tube</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventilator associated pneumonia ( VAP) adds burden to the care of the intensive care patients
      as they may cause the death of the patient or prolong the intensive care stay or complicate
      the illness in other ways. The risk of infection is dependent on the interplay between
      bacteria load into the lungs and the immune status. There has been a lot of focus on bacteria
      load reduction and this includes the use of subglottic suctioning in an attempt to reduce the
      amount of bacteria that may move into the lungs. The Hi Lo tubes which were designed to allow
      subglottic suctioning was significantly effective in reducing the incidence of ventilator
      associated pneumonia compared to normal tubes. A new generation of endotracheal tubes that
      not only incorporate subglottic suctioning but provide a more snug fit into the tracheal by a
      new tapering design may be even more useful to provide the solution for bacterial load
      reduction. Conventional tubes which may furrow on themselves to allow the creation of
      microchannels may aid microaspiration. The taper guard which has facilities for subglottic
      suctioning as well as the strategy to reduce furrowing to the minimum may be the answer to
      the problem of ventilator associated pneumonia. This study is to determine the extent of
      protection this tube has against ventilator associated pneumonia compared with conventional
      endotracheal tubes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology This will be a prospective randomized trial with 2 treatment groups with 100
      patients in each arm. The control group ( Group C) will be intubated with our conventional
      endotracheal tubes and the test group ( Group T) will be intubated with the special Taper
      guard tubes with subglottic suctioning and snug fit facilities.

      All adult patients ( &gt; 18 years of age) admitted into the Intensive Care Unit who are likely
      to receive more than 72 hours of ventilation will be admitted into the trial. The trial has
      been cleared by the Hospital Ethics and informed consent will be obtained from the patient's
      next of kin.

      All patients will have their demographic data collected, the primary reason for ICU
      admission, the APACHE 2 scores, presence of infection at admission, antibiotic use and
      whether they have risk factors for VAP ( previous surgery, trauma, antibiotics usage, reflux
      disease and use of stress ulcer prophylaxis, decreased immune status ) The following
      guidelines modified from the American Thoracic Society 2005 will be used as the basis for
      diagnosing Ventilator Associated Pneumonia.

      Guideline for Diagnosis of Ventilator Associated Pneumonia (VAP)2

        1. Patient ventilated for more than 48 hours.

        2. Suspicion of ventilation associated pneumonia

        3. Presence of a new or progressive infiltrate on chest radiograph.

        4. At least 2 of the following:

             1. Fever, defined as an oral temperature greater than 38 degree C, a tympanic
                temperature greater than 38.5 degree C or a rectal /core temperature greater than
                39 degree C OR hypothermia, defined as a rectal/core body temperature of less than
                35 degree C.

             2. Elevated total peripheral WBC count (greater than 12000/mm3) or greater than 15%
                bands regardless of total peripheral WBC count; or leucopenia with total peripheral
                WBC less than 4500/mm3 (caused by the infection)

             3. New onset of purulent sputum production or other respiratory secretions (e.g.
                tracheal secretions), or a change in the character of sputum or tracheal secretions

             4. Worsening hypoxaemia with reduction in PaO2/ FiO2 greater or equal to 15%

      In addition all patients will have aspirants from the oral cavity (control group) or
      subglottic region (group T) and the lungs ( both group C and group T) sent on alternate days
      for bacterial culture. All tubes will be inflated to a sealing pressure of no leak or up to
      20-25 cm H2O whichever is the lower.

      The sample size has been estimated based on the incidence of ventilation-associated pneumonia
      (VAP) which is the primary outcome measure from other studies1,2. Based on a VAP incidence of
      20% and 6% in each group, 1:1 ratio, 80% power and significance value of 0.05, the number
      required in each group will be 89. Adding 10% for loss to follow-up, the number needed in
      each group will be 100 giving a total of 200 The assignment of each patient to the study will
      be randomized according to computer generated random numbers by the statistician who will not
      be a party in the ongoing clinical part of the research. In addition she will provide the
      allocation sequencing via an opaque envelope when a suitable patient has been identified for
      the assignment of the patient to the 2 groups when informed consent has been obtained. The
      person who intubates the patient with the endotracheal tube will use the tube that has been
      allocated according to the written instruction inside the now opened opaque envelope.

      Patient and the clinical researchers managing the patient cannot be blinded as there are
      obvious differences between the 2 types of endotracheal tubes. However the assessor that will
      determine the presence or absence of the soft signs of ventilator associated pneumonia will
      be blinded to the type of tubes used. The Radiologist who reads the Chest Xrays will not be
      privy to the type of tubes used and the Microbiologist determining the significance of the
      bacteria identified in the oral/subglottic secretions and the tracheal secretions will not be
      aware of the endotracheal tubes used.

      The main outcome measure will be the incidence of ventilator associated pneumonia on each day
      the patient is ventilated. The secondary outcomes will be the length of ventilation, the
      duration of intensive care stay, the duration of hospital stay (pre-intensive care,
      post-intensive care) and the incidence of mortality of the 2 groups.

      Statistics Categorical variables will be analysed using Chi square test while continuous
      variables will be analysed using ANOVA. Intention to treat analysis will be used. Analysis
      will be carried out using the SPSS version 15.0 software. All statistical tests will be
      carried out using a significance level of 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of ventilator associated pneumonia(VAP)</measure>
    <time_frame>72 hours after ventilation initiated to onset of pneumonia</time_frame>
    <description>the incidence of VAP in patients intubated with the Taper guard tube is compared with the incidence of VAP in patients intubated with the ordinary tube. The criteria for diagnosing VAP is from the American Thoracic Society 2005 guidelines for VAP diagnosis. The assessor for VAP diagnosis is blinded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days on the ventilator by the time patient is discharged from ICU or hospital or at time of death</measure>
    <time_frame>participants will be followed for the duration of ventilation, an expected average of 2 weeks</time_frame>
    <description>The number of days patient is on the ventilator will be monitored between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total number of days spent in the intensive care unit by the time of discharge from hospital or death</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>The length of stay in the intensive care unit will be monitored between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days spent in the hospital by the time of discharge or death</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>The length of stay in the hospital will be monitored for the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of deaths in each arm</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>the rate of mortality between the 2 groups will be monitored</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Taper Guard Endotracheal Tube</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional endotracheal tube</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taper Guard Endotracheal Tube</intervention_name>
    <description>comparison of two different endotracheal tubes</description>
    <arm_group_label>Taper Guard Endotracheal Tube</arm_group_label>
    <other_name>Taperguard Evac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional endotracheal tube</intervention_name>
    <description>Sham Comparator</description>
    <arm_group_label>conventional endotracheal tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients above 18 years old admitted into the Intensive Care unit and who is
             to be intubated and likely to receive more than 72 hours of ventilation would be
             admitted into the trial

        Exclusion Criteria:

          -  presence of cavitary lung disease based on chest x-ray findings,

          -  primary lung cancer or another metastatic malignancy to the lungs, or known or
             suspected viral or fungal etiology,

          -  pneumocystis carinii pneumonia,

          -  legionella OR Mycoplasma pneumonia or active tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoo-Kuen Chan, FFARCSI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vineya Rai, MAnesth; EDIC</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohd Shahnaz Hassan, MBBS;MAnesth</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suresh Venogobal, MBBS; FANZCA</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kang-Kwong Wong, MBBS;MAnesth</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohd Yasim Yusof, MBBS;MSc Microbiology</last_name>
    <role>Study Director</role>
    <affiliation>Department of Microbiology, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Foong-Ming Moy, BSc, MSc, MMedSc PH, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Julius Centre University of Malaya, Department of Social &amp; Preventive Medicine, Faculty of Medicine, University of Malaya.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nur Adura Yaakup, MBBS, MRad</last_name>
    <role>Study Director</role>
    <affiliation>Department of Biomedical Imaging, Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoo-Kuen CHAN, FFARCSI</last_name>
    <phone>+6012-2937163</phone>
    <email>chanyk@ummc.edu.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vineya RAI, MAnesth; EDIC</last_name>
    <phone>+60122157175</phone>
    <email>vineya74@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoo-Kuen Chan, FFARCSI</last_name>
      <phone>+6012-2937163</phone>
      <email>chanyk@ummc.edu.my</email>
    </contact>
    <contact_backup>
      <last_name>Vineya Rai, MBBS;MAnesth;EDIC</last_name>
      <phone>+60122157175</phone>
      <email>vineya74@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yoo-Kuen Chan, FFARCSI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vineya Rai, MAnesth;EDIC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohd Shahnaz Hassan, MBBS;MAnesth</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suresh Venogobal, MAnesth, FANZCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kang-Kwong Wong, MBBS;MAnesth</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohd Yasim Yusof, MBBS; MMicrobiology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foong-Ming Moy, BSc, MScMMedScPH, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nur Adura Yaakup, MBBS;MRad</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416.</citation>
    <PMID>15699079</PMID>
  </reference>
  <results_reference>
    <citation>Bo H, He L, Qu J. [Influence of the subglottic secretion drainage on the morbidity of ventilator associated pneumonia in mechanically ventilated patients]. Zhonghua Jie He He Hu Xi Za Zhi. 2000 Aug;23(8):472-4. Chinese.</citation>
    <PMID>11778260</PMID>
  </results_reference>
  <results_reference>
    <citation>Smulders K, van der Hoeven H, Weers-Pothoff I, Vandenbroucke-Grauls C. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. Chest. 2002 Mar;121(3):858-62.</citation>
    <PMID>11888973</PMID>
  </results_reference>
  <results_reference>
    <citation>Lorente L, Lecuona M, Jim√©nez A, Mora ML, Sierra A. Influence of an endotracheal tube with polyurethane cuff and subglottic secretion drainage on pneumonia. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1079-83. Epub 2007 Sep 13.</citation>
    <PMID>17872488</PMID>
  </results_reference>
  <results_reference>
    <citation>Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med. 2011 Aug;39(8):1985-91. doi: 10.1097/CCM.0b013e318218a4d9. Review.</citation>
    <PMID>21478738</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>December 28, 2011</last_update_submitted>
  <last_update_submitted_qc>December 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Chan Yoo Kuen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ventilator associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

